As TLR7 plays a prominent role in the pathogenesis of DM (34), we suspect that TLR7 agonists such as those present in RNA/DNA vaccines utilized for COVID-19 may be sufficient to promote inflammatory signals associated with DM. This evidence concerns the gene TLR7 and COVID-19.